Head and Neck Cancer
- Larynx, Lip, Oral Cavity and PharynxThe BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPrincipal Investigator: Aarti Bhatia
- Larynx, Lip, Oral Cavity and PharynxA Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk FeaturesPrincipal Investigator: Aarti Bhatia
- Esophagus, Larynx, Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCAPrincipal Investigator: Aarti Bhatia
- Anus, Breast, Breast - Female, Breast - Male, Cervix, Colon, Corpus Uteri, Esophagus, Hodgkin's Lymphoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Phase I, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced CancerPrincipal Investigator: Francine Foss
- Larynx, Lip, Oral Cavity and PharynxSingle-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and NeckPrincipal Investigator: Aarti Bhatia